The clinical outcome of Montelukast versus co-enzyme Q10 in adult patients with sepsis: A randomized controlled clinical trial
Authors' conclusion
Montelukast and CoQ10 were tolerable and showed potential benefits as add on therapies in sepsis management.
Study context
- Population
- Adult septic patients in an intensive care unit (ICU)
- Participants
- 90 patients
- Comparison
- Montelukast or CoQ10 added to standard care vs standard care alone
- Controln = 30reference
- Montelukastn = 30
- CoQ10n = 30
- Primary endpoint
- Mortality
- Follow-up
- 28 days
Methodological detailsopen label, three-arm
- Open label
- Three-arm
Primary result
As reported in the abstract
28-day mortality
P = 0.024
Secondary outcomes
Duration of vasopressor — CoQ10 vs Control
P < 0.001
| Outcome | P value |
|---|---|
| Duration of vasopressorMontelukast vs Control | P < 0.001 |
Duration of vasopressor
- Montelukast and CoQ10 comparable
Duration of mechanical ventilation (MV)
- Same pattern as vasopressor duration
SOFA score, procalcitonin, C-reactive protein (CRP), TNF-α, malondialdehyde (MDA)
- Significant positive effect of both montelukast and CoQ10
Safety
%
- Adverse effects — CoQ10
- 20
- Adverse effects — CoQ10: hypotension
- 20
Adverse effects
- Montelukast: no adverse effects
Original publication
The clinical outcome of Montelukast versus co-enzyme Q10 in adult patients with sepsis: A randomized controlled clinical trial. J Crit Care. Published 21 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →